Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (18): 3295-3300.doi: 10.3969/j.issn.1673-8225.2012.18.015

Previous Articles     Next Articles

Protective effect of adenovirus vector mediated rat insulin-like growth factor 1 gene on pancreatic beta cells  

Song Qing1, Qiao Ling-yan2, Tian Fei1, Chen Zhi-hong1, Li Tang1   

  1. 1Department of Pediatrics, Affiliated Hospital of Medical College of Qingdao University, Qingdao  266003, Shandong Province, China; 2Women and Child Hospital of Qingdao, Qingdao  266000, Shandong Province, China
  • Received:2012-01-12 Revised:2012-01-28 Online:2012-04-29 Published:2012-04-29
  • Contact: Li Tang, Doctoral supervisor, Department of Pediatrics, Affiliated Hospital of Medical College of Qingdao University, Qingdao 266003, Shandong Province, China drlitang@hotmail.com
  • About author:Song Qing★, Studying for master’s degree, Department of Pediatrics, Affiliated Hospital of Medical College of Qingdao University, Qingdao 266003, Shandong Province, China songqing3633@126.com
  • Supported by:

    the National Natural Science Foundation of China, No.81170762*; Natural Science Foundation of Shandong, No.Y2008C50*

PDF

338

Abstract:

BACKGROUND: Research shows that the high expression of the rat insulin-like growth factor 1 (rIGF-1) has certain preventive effect on drug induced diabetes.
OBJECTIVE: To investigate the protective effect of adenovirus vector mediated rat rIGF-1 gene on pancreatic β-cells impairment.
METHODS: ①In vitro experiment: the RINm5F cells of pancreatic β-cells were infected with Ad-rIGF-1 and Ad-eGFP gene, each group was treated with 0 or 1.5 mmol/L streptozotocin (STZ) medium. ②In vivo prevention experiment: 60 Kunming mice were randomly divided into four groups: blank control group (without any treatment), diabetes mellitus group (diabetes mellitus model was established), Ad-eGFP group (treated with intraperitoneal injection of Ad-eGFP adenovirus medium) and Ad-rIGF-1 group (treated with intraperitoneal injection of Ad-rIGF-1 adenovirus medium at two weeks early before the establishment of diabetes mellitus model). ③In vivo treatment experiment: 75 Kunming mice were randomly divided into five groups: blank control group (without any treatment), diabetes mellitus group, insulin group, Ad-rIGF-1 group and Ad-rIGF-1 plus insulin group. Corresponding intervention was given to the last three groups before the establishment of diabetes mellitus model.
RESULTS AND CONCLUSION: ①The rIGF-1 was expressed in pancreatic β-cells and could inhibit the apoptosis of STZ induced pancreatic β-cells. ②Prevention experiment showed that the Ad-rIGF-1 group had a lower incidence in diabetes and a lower degree of average blood glucose and the inflammatory infiltration was lighter. ③Compared with diabetes mellitus group and insulin group, the inflammatory infiltration was lighter in Ad-rIGF-1 group and Ad-rIGF-1plus insulin group and the rIGF-1 was highly expressed in part of the islet cells; serum C peptide detected by enzyme linked immunosorbent assay showed a lower degree in insulin group, Ad-rIGF-1 group and Ad-rIGF-1 plus insulin group, however it had no difference between groups (P > 0.05). These results suggested that locally produced rIGF-1 in pancreatic β-cells could maintain the β cells function, promote islet survival rate and prevent and mitigate the STZ-induced type 1 diabetes mellitus. The effect of rIGF-1 transduction combined with insulin subcutaneous injection on the protection of the function of residual islet cells in early diabetes models was not obvious.

CLC Number: